Testing effectiveness (Phase 2)Ended earlyNCT05764395
What this trial is testing
Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors
Who this might be right for
Clinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic Melanoma+2 more
Vanderbilt-Ingram Cancer Center 7